A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL

To be part of this study, you need to be an adult aged 18 or older and have a confirmed diagnosis of chronic lymphocytic leukaemia (CLL). Importantly, your CLL needs to be active, meaning it's causing problems that require treatment, or it has come back after you've had treatment before.

Your doctors would need to confirm that your CLL meets specific criteria. For example, they'll check your blood for certain types of cells and how many there are. They'll also make sure your general health is good enough to take part, based on a standard health score. Your CLL must also show traces of a specific marker called CD20.

You would not be able to join if your CLL is causing severe anaemia (low red blood cells), low platelets (cells that help blood clot), an enlarged spleen or lymph nodes that are growing quickly or causing symptoms, or if your white blood cell count is rapidly increasing. There are other detailed medical conditions that your study doctor will check very carefully to make sure the study is right and safe for you.

If you decide to take part in this study, you would receive either the new medicine, acalabrutinib, or one of the standard treatments (rituximab with idelalisib, or rituximab with bendamustine). Which treatment you receive would be decided by chance, like flipping a coin. You would have regular visits to the clinic for medical check-ups, blood tests, and to get your study medicine. These visits would help the doctors keep a close eye on your health and how you're responding to the treatment. The total duration for which you would stay on the study treatment would depend on how your CLL responds, but you would have regular follow-up even after stopping the treatment.